APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pharmaceutical Impurity Analysis Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pharmaceutical Impurity Analysis Service Market Analysis and Forecast 2026-2032

Report ID 17421436021 January 2026192 pages

Choose your research edition.

Industry ResearchPharmaceutical Impurity Analysis Service Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmaceutical Impurity Analysis Service Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Pharmaceutical Impurity Analysis Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmaceutical Impurity Analysis Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmaceutical Impurity Analysis Service Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Pharmaceutical Impurity Analysis Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pharmaceutical Impurity Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pharmaceutical Impurity Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pharmaceutical Impurity Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pharmaceutical Impurity Analysis Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pharmaceutical Impurity Analysis Service include Intertek, Creative Proteomics, Emery Pharma, Agilent, Vimta, Alfa Chemistry, Eurofins, Alera Labs and Impact Analytical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pharmaceutical Impurity Analysis Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pharmaceutical Impurity Analysis Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmaceutical Impurity Analysis Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pharmaceutical Impurity Analysis Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmaceutical Impurity Analysis Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmaceutical Impurity Analysis Service revenue, projected growth trends, production technology, application and end-user industry.

Pharmaceutical Impurity Analysis Service Segment by Company

Intertek

Creative Proteomics

Emery Pharma

Agilent

Vimta

Alfa Chemistry

Eurofins

Alera Labs

Impact Analytical

Leeder Analytical

Nelson Labs

Reading Scientific Services

Regis Technologies

Selvita

SGS

Pharmaceutical Impurity Analysis Service Segment by Type

Organic Impurity Analysis

Inorganic Impurity Analysis

Residual Solvent Analysis

Others

Pharmaceutical Impurity Analysis Service Segment by Application

Pharmaceutical Industry

Agriculture

Biotechnology

Others

Pharmaceutical Impurity Analysis Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Impurity Analysis Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Impurity Analysis Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Impurity Analysis Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pharmaceutical Impurity Analysis Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pharmaceutical Impurity Analysis Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmaceutical Impurity Analysis Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pharmaceutical Impurity Analysis Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Organic Impurity Analysis Major Player Table 3. Inorganic Impurity Analysis Major Player Table 4. Residual Solvent Analysis Major Player Table 5. Others Major Player Table 6. Global Pharmaceutical Impurity Analysis Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Pharmaceutical Industry Major Player Table 8. Agriculture Major Player Table 9. Biotechnology Major Player Table 10. Others Major Player Table 11. Pharmaceutical Impurity Analysis Service Industry Trends Table 12. Pharmaceutical Impurity Analysis Service Industry Drivers Table 13. Pharmaceutical Impurity Analysis Service Industry Opportunities and Challenges Table 14. Pharmaceutical Impurity Analysis Service Industry Restraints Table 15. Global Pharmaceutical Impurity Analysis Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Pharmaceutical Impurity Analysis Service Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Pharmaceutical Impurity Analysis Service Market Share by Region (2021-2026) Table 18. Global Pharmaceutical Impurity Analysis Service Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Pharmaceutical Impurity Analysis Service Market Share by Region (2027-2032) Table 20. Global Pharmaceutical Impurity Analysis Service Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Players (2021-2026) Table 22. Global Pharmaceutical Impurity Analysis Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Pharmaceutical Impurity Analysis Service Key Players Headquarters & Area Served Table 24. Global Pharmaceutical Impurity Analysis Service Players, Product Type & Application Table 25. Global Pharmaceutical Impurity Analysis Service Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Pharmaceutical Impurity Analysis Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Pharmaceutical Impurity Analysis Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Type (2021-2026) Table 32. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Type (2027-2032) Table 33. Global Pharmaceutical Impurity Analysis Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Application (2021-2026) Table 37. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Application (2027-2032) Table 38. Intertek Company Information Table 39. Intertek Business Overview Table 40. Intertek Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Intertek Pharmaceutical Impurity Analysis Service Product Portfolio Table 42. Intertek Recent Development Table 43. Creative Proteomics Company Information Table 44. Creative Proteomics Business Overview Table 45. Creative Proteomics Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Creative Proteomics Pharmaceutical Impurity Analysis Service Product Portfolio Table 47. Creative Proteomics Recent Development Table 48. Emery Pharma Company Information Table 49. Emery Pharma Business Overview Table 50. Emery Pharma Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Emery Pharma Pharmaceutical Impurity Analysis Service Product Portfolio Table 52. Emery Pharma Recent Development Table 53. Agilent Company Information Table 54. Agilent Business Overview Table 55. Agilent Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Agilent Pharmaceutical Impurity Analysis Service Product Portfolio Table 57. Agilent Recent Development Table 58. Vimta Company Information Table 59. Vimta Business Overview Table 60. Vimta Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Vimta Pharmaceutical Impurity Analysis Service Product Portfolio Table 62. Vimta Recent Development Table 63. Alfa Chemistry Company Information Table 64. Alfa Chemistry Business Overview Table 65. Alfa Chemistry Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Alfa Chemistry Pharmaceutical Impurity Analysis Service Product Portfolio Table 67. Alfa Chemistry Recent Development Table 68. Eurofins Company Information Table 69. Eurofins Business Overview Table 70. Eurofins Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Eurofins Pharmaceutical Impurity Analysis Service Product Portfolio Table 72. Eurofins Recent Development Table 73. Alera Labs Company Information Table 74. Alera Labs Business Overview Table 75. Alera Labs Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Alera Labs Pharmaceutical Impurity Analysis Service Product Portfolio Table 77. Alera Labs Recent Development Table 78. Impact Analytical Company Information Table 79. Impact Analytical Business Overview Table 80. Impact Analytical Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Impact Analytical Pharmaceutical Impurity Analysis Service Product Portfolio Table 82. Impact Analytical Recent Development Table 83. Leeder Analytical Company Information Table 84. Leeder Analytical Business Overview Table 85. Leeder Analytical Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Leeder Analytical Pharmaceutical Impurity Analysis Service Product Portfolio Table 87. Leeder Analytical Recent Development Table 88. Nelson Labs Company Information Table 89. Nelson Labs Business Overview Table 90. Nelson Labs Pharmaceutical Impurity Analysis Service Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Nelson Labs Pharmaceutical Impurity Analysis Service Product Portfolio Table 92. Nelson Labs Recent Development Table 93. Reading Scientific Services Company Information Table 94. Reading Scientific Services Business Overview Table 95. Reading Scientific Services Pharmaceutical Impurity Analysis Service Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Reading Scientific Services Pharmaceutical Impurity Analysis Service Product Portfolio Table 97. Reading Scientific Services Recent Development Table 98. Regis Technologies Company Information Table 99. Regis Technologies Business Overview Table 100. Regis Technologies Pharmaceutical Impurity Analysis Service Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Regis Technologies Pharmaceutical Impurity Analysis Service Product Portfolio Table 102. Regis Technologies Recent Development Table 103. Selvita Company Information Table 104. Selvita Business Overview Table 105. Selvita Pharmaceutical Impurity Analysis Service Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Selvita Pharmaceutical Impurity Analysis Service Product Portfolio Table 107. Selvita Recent Development Table 108. SGS Company Information Table 109. SGS Business Overview Table 110. SGS Pharmaceutical Impurity Analysis Service Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. SGS Pharmaceutical Impurity Analysis Service Product Portfolio Table 112. SGS Recent Development Table 113. North America Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026) & (US$ Million) Table 119. North America Pharmaceutical Impurity Analysis Service Revenue by Country (US$ Million) & (2027-2032) Table 120. Europe Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 123. Europe Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 124. Europe Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Europe Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Pharmaceutical Impurity Analysis Service Revenue by Country (US$ Million) & (2027-2032) Table 127. China Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 128. China Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 129. China Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 130. China Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 132. Asia Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 133. Asia Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 134. Asia Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Pharmaceutical Impurity Analysis Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Asia Pharmaceutical Impurity Analysis Service Revenue by Region (US$ Million) & (2021-2026) Table 137. Asia Pharmaceutical Impurity Analysis Service Revenue by Region (US$ Million) & (2027-2032) Table 138. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026) & (US$ Million) Table 139. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032) & (US$ Million) Table 140. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026) & (US$ Million) Table 141. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032) & (US$ Million) Table 142. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026) & (US$ Million) Table 144. SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country (US$ Million) & (2027-2032) Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Pharmaceutical Impurity Analysis Service Image Figure 2. Global Pharmaceutical Impurity Analysis Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmaceutical Impurity Analysis Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Organic Impurity Analysis Image Figure 5. Inorganic Impurity Analysis Image Figure 6. Residual Solvent Analysis Image Figure 7. Others Image Figure 8. Global Pharmaceutical Impurity Analysis Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Pharmaceutical Impurity Analysis Service Market Size Share 2021 VS 2025 VS 2032 Figure 10. Pharmaceutical Industry Image Figure 11. Agriculture Image Figure 12. Biotechnology Image Figure 13. Others Image Figure 14. Global Pharmaceutical Impurity Analysis Service Market Size (US$ Million) & (2021-2032) Figure 15. Global Pharmaceutical Impurity Analysis Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Pharmaceutical Impurity Analysis Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Pharmaceutical Impurity Analysis Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Pharmaceutical Impurity Analysis Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Pharmaceutical Impurity Analysis Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Type (2021-2032) Figure 22. Global Pharmaceutical Impurity Analysis Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Application (2021-2032) Figure 25. North America Pharmaceutical Impurity Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032) Figure 27. North America Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032) Figure 28. North America Pharmaceutical Impurity Analysis Service Revenue Share by Country (2021-2032) Figure 29. United States Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Pharmaceutical Impurity Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032) Figure 34. Europe Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032) Figure 35. Europe Pharmaceutical Impurity Analysis Service Revenue Share by Country (2021-2032) Figure 36. Germany Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Pharmaceutical Impurity Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032) Figure 46. China Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032) Figure 47. Asia Pharmaceutical Impurity Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032) Figure 49. Asia Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032) Figure 50. Asia Pharmaceutical Impurity Analysis Service Revenue Share by Region (2021-2032) Figure 51. Japan Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Pharmaceutical Impurity Analysis Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032) Figure 59. SAMEA Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032) Figure 60. SAMEA Pharmaceutical Impurity Analysis Service Revenue Share by Country (2021-2032) Figure 61. Brazil Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Pharmaceutical Impurity Analysis Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Organic Impurity Analysis
  • Inorganic Impurity Analysis
  • Residual Solvent Analysis
  • Others
Applications
  • Pharmaceutical Industry
  • Agriculture
  • Biotechnology
  • Others
Companies covered
  • Intertek
  • Creative Proteomics
  • Emery Pharma
  • Agilent
  • Vimta
  • Alfa Chemistry
  • Eurofins
  • Alera Labs
  • Impact Analytical
  • Leeder Analytical
  • Nelson Labs
  • Reading Scientific Services
  • Regis Technologies
  • Selvita
  • SGS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pharmaceutical Impurity Analysis Service Market by Type
  3. 1.2.1 Global Pharmaceutical Impurity Analysis Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Organic Impurity Analysis
  5. 1.2.3 Inorganic Impurity Analysis
  6. 1.2.4 Residual Solvent Analysis
  7. 1.2.5 Others
  8. 1.3 Pharmaceutical Impurity Analysis Service Market by Application
  9. 1.3.1 Global Pharmaceutical Impurity Analysis Service Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Pharmaceutical Industry
  11. 1.3.3 Agriculture
  12. 1.3.4 Biotechnology
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Pharmaceutical Impurity Analysis Service Market Dynamics
  1. 2.1 Pharmaceutical Impurity Analysis Service Industry Trends
  2. 2.2 Pharmaceutical Impurity Analysis Service Industry Drivers
  3. 2.3 Pharmaceutical Impurity Analysis Service Industry Opportunities and Challenges
  4. 2.4 Pharmaceutical Impurity Analysis Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pharmaceutical Impurity Analysis Service Market Perspective (2021-2032)
  2. 3.2 Global Pharmaceutical Impurity Analysis Service Growth Trends by Region
  3. 3.2.1 Global Pharmaceutical Impurity Analysis Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pharmaceutical Impurity Analysis Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Pharmaceutical Impurity Analysis Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pharmaceutical Impurity Analysis Service Revenue by Players
  2. 4.1.1 Global Pharmaceutical Impurity Analysis Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pharmaceutical Impurity Analysis Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pharmaceutical Impurity Analysis Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pharmaceutical Impurity Analysis Service Key Players Headquarters & Area Served
  7. 4.4 Global Pharmaceutical Impurity Analysis Service Players, Product Type & Application
  8. 4.5 Global Pharmaceutical Impurity Analysis Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pharmaceutical Impurity Analysis Service Market CR5 and HHI
  11. 4.6.3 2025 Pharmaceutical Impurity Analysis Service Tier 1, Tier 2, and Tier 3
5 Pharmaceutical Impurity Analysis Service Market Size by Type
  1. 5.1 Global Pharmaceutical Impurity Analysis Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2032)
  3. 5.3 Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Type (2021-2032)
6 Pharmaceutical Impurity Analysis Service Market Size by Application
  1. 6.1 Global Pharmaceutical Impurity Analysis Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2032)
  3. 6.3 Global Pharmaceutical Impurity Analysis Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Intertek
  2. 7.1.1 Intertek Company Information
  3. 7.1.2 Intertek Business Overview
  4. 7.1.3 Intertek Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Intertek Pharmaceutical Impurity Analysis Service Product Portfolio
  6. 7.1.5 Intertek Recent Developments
  7. 7.2 Creative Proteomics
  8. 7.2.1 Creative Proteomics Company Information
  9. 7.2.2 Creative Proteomics Business Overview
  10. 7.2.3 Creative Proteomics Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Creative Proteomics Pharmaceutical Impurity Analysis Service Product Portfolio
  12. 7.2.5 Creative Proteomics Recent Developments
  13. 7.3 Emery Pharma
  14. 7.3.1 Emery Pharma Company Information
  15. 7.3.2 Emery Pharma Business Overview
  16. 7.3.3 Emery Pharma Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Emery Pharma Pharmaceutical Impurity Analysis Service Product Portfolio
  18. 7.3.5 Emery Pharma Recent Developments
  19. 7.4 Agilent
  20. 7.4.1 Agilent Company Information
  21. 7.4.2 Agilent Business Overview
  22. 7.4.3 Agilent Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Agilent Pharmaceutical Impurity Analysis Service Product Portfolio
  24. 7.4.5 Agilent Recent Developments
  25. 7.5 Vimta
  26. 7.5.1 Vimta Company Information
  27. 7.5.2 Vimta Business Overview
  28. 7.5.3 Vimta Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Vimta Pharmaceutical Impurity Analysis Service Product Portfolio
  30. 7.5.5 Vimta Recent Developments
  31. 7.6 Alfa Chemistry
  32. 7.6.1 Alfa Chemistry Company Information
  33. 7.6.2 Alfa Chemistry Business Overview
  34. 7.6.3 Alfa Chemistry Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Alfa Chemistry Pharmaceutical Impurity Analysis Service Product Portfolio
  36. 7.6.5 Alfa Chemistry Recent Developments
  37. 7.7 Eurofins
  38. 7.7.1 Eurofins Company Information
  39. 7.7.2 Eurofins Business Overview
  40. 7.7.3 Eurofins Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eurofins Pharmaceutical Impurity Analysis Service Product Portfolio
  42. 7.7.5 Eurofins Recent Developments
  43. 7.8 Alera Labs
  44. 7.8.1 Alera Labs Company Information
  45. 7.8.2 Alera Labs Business Overview
  46. 7.8.3 Alera Labs Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Alera Labs Pharmaceutical Impurity Analysis Service Product Portfolio
  48. 7.8.5 Alera Labs Recent Developments
  49. 7.9 Impact Analytical
  50. 7.9.1 Impact Analytical Company Information
  51. 7.9.2 Impact Analytical Business Overview
  52. 7.9.3 Impact Analytical Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Impact Analytical Pharmaceutical Impurity Analysis Service Product Portfolio
  54. 7.9.5 Impact Analytical Recent Developments
  55. 7.10 Leeder Analytical
  56. 7.10.1 Leeder Analytical Company Information
  57. 7.10.2 Leeder Analytical Business Overview
  58. 7.10.3 Leeder Analytical Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Leeder Analytical Pharmaceutical Impurity Analysis Service Product Portfolio
  60. 7.10.5 Leeder Analytical Recent Developments
  61. 7.11 Nelson Labs
  62. 7.11.1 Nelson Labs Company Information
  63. 7.11.2 Nelson Labs Business Overview
  64. 7.11.3 Nelson Labs Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Nelson Labs Pharmaceutical Impurity Analysis Service Product Portfolio
  66. 7.11.5 Nelson Labs Recent Developments
  67. 7.12 Reading Scientific Services
  68. 7.12.1 Reading Scientific Services Company Information
  69. 7.12.2 Reading Scientific Services Business Overview
  70. 7.12.3 Reading Scientific Services Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Reading Scientific Services Pharmaceutical Impurity Analysis Service Product Portfolio
  72. 7.12.5 Reading Scientific Services Recent Developments
  73. 7.13 Regis Technologies
  74. 7.13.1 Regis Technologies Company Information
  75. 7.13.2 Regis Technologies Business Overview
  76. 7.13.3 Regis Technologies Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Regis Technologies Pharmaceutical Impurity Analysis Service Product Portfolio
  78. 7.13.5 Regis Technologies Recent Developments
  79. 7.14 Selvita
  80. 7.14.1 Selvita Company Information
  81. 7.14.2 Selvita Business Overview
  82. 7.14.3 Selvita Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Selvita Pharmaceutical Impurity Analysis Service Product Portfolio
  84. 7.14.5 Selvita Recent Developments
  85. 7.15 SGS
  86. 7.15.1 SGS Company Information
  87. 7.15.2 SGS Business Overview
  88. 7.15.3 SGS Pharmaceutical Impurity Analysis Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 SGS Pharmaceutical Impurity Analysis Service Product Portfolio
  90. 7.15.5 SGS Recent Developments
8 North America
  1. 8.1 North America Pharmaceutical Impurity Analysis Service Revenue (2021-2032)
  2. 8.2 North America Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032)
  5. 8.3 North America Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032)
  9. 8.5 North America Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Pharmaceutical Impurity Analysis Service Revenue by Country
  11. 8.6.1 North America Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Pharmaceutical Impurity Analysis Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pharmaceutical Impurity Analysis Service Revenue (2021-2032)
  2. 9.2 Europe Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032)
  5. 9.3 Europe Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032)
  9. 9.5 Europe Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pharmaceutical Impurity Analysis Service Revenue by Country
  11. 9.6.1 Europe Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pharmaceutical Impurity Analysis Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pharmaceutical Impurity Analysis Service Revenue (2021-2032)
  2. 10.2 China Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2032)
  3. 10.2.1 China Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026)
  4. 10.2.2 China Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032)
  5. 10.3 China Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032)
  6. 10.4 China Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2032)
  7. 10.4.1 China Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026)
  8. 10.4.2 China Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032)
  9. 10.5 China Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pharmaceutical Impurity Analysis Service Revenue (2021-2032)
  2. 11.2 Asia Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032)
  5. 11.3 Asia Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032)
  9. 11.5 Asia Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pharmaceutical Impurity Analysis Service Revenue by Country
  11. 11.6.1 Asia Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pharmaceutical Impurity Analysis Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pharmaceutical Impurity Analysis Service Revenue (2021-2032)
  2. 12.2 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pharmaceutical Impurity Analysis Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pharmaceutical Impurity Analysis Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country
  11. 12.6.1 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pharmaceutical Impurity Analysis Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst